What question did this study set out to answer?

To determine whether dexmedetomidine administration interferes with the induction or successful ablation of supraventricular tachyarrhythmias during electrophysiological studies.

October 25, 2016Pediatric Anesthesia

Dexmedetomidine use in patients undergoing electrophysiological study for supraventricular tachyarrhythmias

View Full Paper

Ask AI

Bookmark

Why the study?

Does dexmedetomidine use inhibit the induction and successful ablation of supraventricular tachyarrhythmias in pediatric patients undergoing electrophysiological studies?

Population

Pediatric patients presenting to the cardiac catheterization laboratory for diagnosis or treatment of…

Comparison

Dexmedetomidine administered as an infusion with… vs No dexmedetomidine

Design

Cohort

Authors

CTChristopher F. TirottaMiami Children's Hospital TNTuan NguyenOlive View-UCLA Medical Center SFSteven B. FishbergerPediatric / Congenital Cardiology

Discussion

Member takes

Implication

Dexmedetomidine may not inhibit arrhythmia induction in pediatric EP studies; leaves open need for prospective trials before practice change.

Key Points

To determine whether dexmedetomidine administration interferes with the induction or successful ablation of supraventricular tachyarrhythmias during electrophysiological studies.
Retrospective observational cohort study reviewing catheterization laboratory records since 2007 for patients undergoing electrophysiological evaluation of supraventricular tachyarrhythmias by a single electrophysiologist.
Patients were stratified across three anesthetic regimens: no dexmedetomidine (Group 1), dexmedetomidine infusion at 0.5–1 µg·kg⁻¹·h⁻¹ (Group 2), or dexmedetomidine bolus of 0.5–1 µg·kg⁻¹ followed by continuous infusion (Group 3).
Assessed outcomes included anesthetic requirements, need for rhythm-altering drugs (isoproterenol, adenosine), arrhythmia inducibility, acute ablation success, and post-procedural recurrence.
Dexmedetomidine administration significantly reduced total propofol requirements compared to the non-dexmedetomidine cohort (χ²(2) = 48.2, P < 0.001).
Patients who did not receive dexmedetomidine required preablation isoproterenol significantly less often than those in the dexmedetomidine groups (χ²(2) = 15.2, P < 0.01).
Arrhythmia inducibility, procedural ablation rate, and long-term recurrence rates did not differ significantly between groups despite increased isoproterenol utilization.

Structured PICO

Does dexmedetomidine use inhibit the induction and successful ablation of supraventricular tachyarrhythmias in pediatric patients undergoing electrophysiological studies?

Population

Pediatric patients presenting to the cardiac catheterization laboratory for diagnosis or treatment of supraventricular tachyarrhythmias (SVT)

Intervention

Dexmedetomidine administered as an infusion (0.5-1 μg/kg/h) with or without a prior bolus (0.5-1 μg/kg)

Comparator

No dexmedetomidine

Outcome

Ability to induce the arrhythmia and successful ablation of the arrhythmia

Dexmedetomidine can be safely used for sedation during pediatric electrophysiological studies for SVT without interfering with arrhythmia induction or ablation success, though it may increase the need for isoproterenol.

Cite This Study

Tirotta et al. (2016) studied this question.

synapsesocial.com/papers/6a71ff4f5d37378ac1def462 https://doi.org/10.1111/pan.13019

View Full Paper

Ask AI

Bookmark

Implication

Dexmedetomidine may not inhibit arrhythmia induction in pediatric EP studies; leaves open need for prospective trials before practice change.

Dexmedetomidine use in patients undergoing electrophysiological study for supraventricular tachyarrhythmias

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Dexmedetomidine use in patients undergoing electrophysiological study for supraventricular tachyarrhythmias

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider